Evidence map›Paper›PMID 41310662›Full record

ArticleJournal of translational medicine2025

Association of multi-site microbial features with malignancy risk in pulmonary ground-glass nodules and identification of predictive biomarkers: a prospective multicenter cohort study.

Chunxia Huang, Jiawei He, Xi Fu, Yang Zhong, Yuling Jiang, Aoling Yang, Hengzhou Lai, Qian Wang, Shiyan Tan, Xueke Li and 8 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Chunxia Huang *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Jiawei He *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Xi Fu *Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Yang ZhongHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Yuling JiangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Aoling YangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Hengzhou LaiHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Qian WangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Shiyan TanHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Xueke LiHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Yifang JiangHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China.
Yuli QuCollege of Artificial Intelligence, Xi'an Jiaotong University, Xian, Shanxi, 710061, China.
Xiang ZhuangDepartment of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610042, China.
Ping XiaoDepartment of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610042, China.
Yifeng RenHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China. ryftcm.dr@yahoo.com.
Chuan ZhengHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China. zhengchuan@cdutcm.edu.cn.
Fengming YouHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China. yfmdoc@163.com.
Qiong MaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 610072, China. Maqiong.Dr@outlook.com.

Funding

Key Research and Development Project of Chengdu Science and Technology Bureau 2024-YF05-01921-SNNature Science Foundation of China 82405354Nature Science Foundation of China 82405359Sichuan Province Science and Technology Support Program 2025ZNSFSC1850the Joint Innovation Fund of Health Commission of Chengdu and Chengdu University of Traditional Chinese Medicine WXLH2O24O311Othe Postdoctoral Fellowship Program and China Postdoctoral Science Foundation BX20250214
6 · The paper itself

Abstract

backgroundEmerging evidence links multi-anatomical site microbiota of the respiratory tract to lung cancer development; however, its potential for predicting the malignancy risk of ground-glass nodules (GGN) has not been systematically explored.

methodsA total of 748 patients with GGN from three medical centers were prospectively enrolled. Nasopharyngeal swabs and bronchoalveolar lavage fluid (BALF) samples were collected from these patients. During the 2-year follow-up, the patients were divided into a benign group (B_GGN, n = 251) and a malignant (M_GGN, n = 136) group. We used 16S rRNA gene sequencing to analyze the structure of the respiratory microbiota. Additionally, seven machine learning algorithms were integrated to construct and screen the best model for predicting the malignancy risk of GGN. The Shapley Additive Explanations method was utilized to identify key microbial markers, and their specificity was verified using an external independent dataset. Furthermore, co-occurrence network analysis and PICRUSt2 functional prediction were conducted to explore the functional changes in microbial communities during the malignant progression of GGN.

resultsThe respiratory microbiota of patients with GGN displayed distinct site-specific distribution characteristics, with the nasopharyngeal microbiota demonstrating significant advantages in predicting the malignancy risk of GGN. The LightGBM prediction model based on the nasopharyngeal microbiota exhibited the best diagnostic performance (AUC = 0.808, 95% CI: 0.769–0.850). Fusobacterium, Gemella, TM7x, Lachnoanaerobaculum, Rothia, and Veillonella were identified as key biomarkers. The specificity of these markers has been validated in multiple external cohorts and can enhance the overall predictive performance of traditional clinical models, such as the Mayo Clinic Model (AUC = 0.835, 95% CI: 0.801–0.873). Functional prediction analysis suggested that the malignant progression of GGN may be associated with dysregulation of amino acid metabolism and immune-related pathways.

conclusionsThe nasopharyngeal microbiota might serve as a non-invasive and reliable biomarker for early prediction of the malignant risk of GGN, exhibiting potential application value in the clinical management of pulmonary nodules.

trial registrationChiCTR2200062140; Date of registration: 25/07/2022.

Indexed as

Biomarkers, TumorLung NeoplasmsMicrobiotaFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsRNA, Ribosomal, 16SROC CurveBiomarkers, TumorRNA, Ribosomal, 16SBiomarkerLung cancerMachine learningMulti-site microbiotaPulmonary ground-glass nodules

Identifiers

PMID41310662
PMCPMC13088588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.